NIH, Sponsors, Non-Profits Form Accelerating Medicines Partnership
The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership
The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership (AMP) in the hopes of accelerating biomarker identification and drug targets in four diseases—Alzheimer's, Type II diabetes, rheumatoid arthritis and lupus—through data sharing. At the foundation of the partnership is the agreement that the data and analyses generated will be made publicly available to the broad biomedical community.
The AMP partners, along with the NIH include FDA, as well as biopharma sponsors AbbVie, Biogen, BMS, GSK, J&J, Lilly, Merck, Pfizer, Sanofi and Takeda. Major disease associations include the Alzheimer’s Association, USAgainstAlzheimer’s, American Diabetes Association, Lupus Foundation of America, and the Rheumatology Research Foundation. All partners have developed research plans and are sharing costs, expertise, and resources in an integrated governance structure. The three- to five-year, milestone-driven pilot projects in these disease areas could set the stage for broadening AMP to other diseases and conditions.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
